JP2013177430A5 - - Google Patents

Download PDF

Info

Publication number
JP2013177430A5
JP2013177430A5 JP2013111446A JP2013111446A JP2013177430A5 JP 2013177430 A5 JP2013177430 A5 JP 2013177430A5 JP 2013111446 A JP2013111446 A JP 2013111446A JP 2013111446 A JP2013111446 A JP 2013111446A JP 2013177430 A5 JP2013177430 A5 JP 2013177430A5
Authority
JP
Japan
Prior art keywords
cells
cancer
killed
dendritic
monocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013111446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013177430A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013177430A publication Critical patent/JP2013177430A/ja
Publication of JP2013177430A5 publication Critical patent/JP2013177430A5/ja
Pending legal-status Critical Current

Links

JP2013111446A 2006-06-30 2013-05-28 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞 Pending JP2013177430A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81791606P 2006-06-30 2006-06-30
US60/817,916 2006-06-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009518581A Division JP2009542714A (ja) 2006-06-30 2007-06-29 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015207617A Division JP6134763B2 (ja) 2006-06-30 2015-10-22 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Publications (2)

Publication Number Publication Date
JP2013177430A JP2013177430A (ja) 2013-09-09
JP2013177430A5 true JP2013177430A5 (enExample) 2014-06-26

Family

ID=38895372

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009518581A Pending JP2009542714A (ja) 2006-06-30 2007-06-29 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
JP2013111446A Pending JP2013177430A (ja) 2006-06-30 2013-05-28 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
JP2015207617A Active JP6134763B2 (ja) 2006-06-30 2015-10-22 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009518581A Pending JP2009542714A (ja) 2006-06-30 2007-06-29 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015207617A Active JP6134763B2 (ja) 2006-06-30 2015-10-22 ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞

Country Status (8)

Country Link
US (1) US20080031900A1 (enExample)
EP (2) EP2630968A1 (enExample)
JP (3) JP2009542714A (enExample)
KR (1) KR20090033375A (enExample)
CN (1) CN101511384A (enExample)
AU (1) AU2007269245B2 (enExample)
CA (1) CA2691346A1 (enExample)
WO (1) WO2008005859A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149382A2 (en) * 2008-06-06 2009-12-10 Baylor Research Institute Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
CN102933228A (zh) * 2010-03-15 2013-02-13 宾夕法尼亚大学董事会 制备和储存活化的、成熟树突细胞的体系和方法
AR087380A1 (es) * 2011-07-27 2014-03-19 Baylor Res Inst Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas
SG11201401631VA (en) * 2011-10-20 2014-05-29 California Stem Cell Inc Antigen presenting cancer vaccine with gamma interferon
PL2591798T3 (pl) 2011-11-09 2015-04-30 Werner Lubitz Szczepionka do zastosowania w immunoterapii nowotworów
CA2896994A1 (en) 2012-12-28 2014-07-03 Amphera B.V. Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells
EP2787005A1 (en) 2013-04-02 2014-10-08 Activartis Biotech GmbH Targeted cancer immune therapy
WO2016011347A1 (en) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Multi-dose injection ready dendritic cell vaccines and combination therapy for cancer
CN107148470A (zh) * 2014-09-04 2017-09-08 新加坡科技研究局 上调癌干细胞标志物以产生抗原特异性细胞毒性效应t细胞的方法
WO2016064899A1 (en) * 2014-10-21 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
CN107532146A (zh) * 2015-03-17 2018-01-02 国立大学法人信州大学 通过使用ifn的非贴壁培养制备树突状细胞的方法
ES2964746T3 (es) * 2015-12-30 2024-04-09 Celgene Corp Métodos de producción de linfocitos T y linfocitos T producidos mediante el mismo
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CN108567977B (zh) * 2017-03-13 2022-04-12 复旦大学 一种免疫增强剂、免疫治疗药物组合物及其制备与用途
KR20190057938A (ko) 2017-11-21 2019-05-29 이근량 버스닥트의 다점 온도감지 및 광학적 경보시스템
US12329807B2 (en) * 2018-01-18 2025-06-17 Meganano Biotech, Inc. Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases
WO2019204391A1 (en) * 2018-04-19 2019-10-24 Robert Caruso Cryo-inactivated cancer cells for cancer immunotherapy
KR102930963B1 (ko) * 2019-03-01 2026-02-25 시애틀 프로젝트 코포레이션 T 세포 수용체의 선택
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP2023013211A (ja) * 2021-07-15 2023-01-26 大日本印刷株式会社 細胞医薬品の提供方法、細胞医薬品用ラベルの作成方法、情報処理方法、プログラム、細胞医薬品、細胞医薬品容器および細胞医薬品提供システム
WO2024112647A1 (en) 2022-11-23 2024-05-30 Jjr&D, Llc Cancer cytotoxic exosome formulations and methods for use in treating cancer
WO2024256477A1 (en) * 2023-06-13 2024-12-19 Pdc Line Pharma Sa Method for preparing plasmacytoid dendritic cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633929B1 (en) 1992-04-01 2004-03-03 The Rockefeller University METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS
US6821778B1 (en) * 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
EP1007720B1 (en) * 1997-04-15 2008-03-05 Dana Farber Cancer Institute, Inc. Dendritic cell hybrids
US6207170B1 (en) * 1998-01-16 2001-03-27 Biomira U.S.A., Inc. Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes
JP2002504322A (ja) * 1998-02-20 2002-02-12 ザ ロックフェラー ユニバーシティー 樹状細胞に対するアポトーシス細胞介在抗原提示
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
CA2542686A1 (en) * 2003-10-15 2005-05-06 Istituto Superiore Di Sanita Colorectal cancer antigen
US20050214268A1 (en) * 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US20060045883A1 (en) * 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
US20060140983A1 (en) * 2004-10-25 2006-06-29 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies

Similar Documents

Publication Publication Date Title
JP2013177430A5 (enExample)
JP2010514455A5 (enExample)
ATE522600T1 (de) Anti-tumor impfstoff aus normalen chemisch modifizierten cd4+ zellen
Hope et al. Striking a balance—cellular and molecular drivers of memory T cell development and responses to chronic stimulation
Andersen The specific targeting of immune regulation: T-cell responses against Indoleamine 2, 3-dioxygenase
JP2014514927A5 (enExample)
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
JP2015131795A5 (enExample)
MX391015B (es) Composiciones de nanoparticulas y usos de las mismas
BR112019001656A2 (pt) composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo
BR112020015512A2 (pt) método de produção de células exterminadoras naturais e composição para tratamento de câncer
RU2012127685A (ru) Устройства и способы для активной клеточной иммунотерапии рака путем применения опухолевых клеток, уничтоженных при помощи высокого гидростатического давления, и дендритных клеток
Liu et al. Maintenance and recall of memory T cell populations against tuberculosis: Implications for vaccine design
JP2012021028A5 (enExample)
JP2018522880A5 (enExample)
JP2014533938A5 (enExample)
JP2018016651A (ja) 能動免疫療法のためのＴｈ１ワクチン接種プライミング
JP2014530627A5 (enExample)
Shimabukuro-Vornhagen et al. The ratio between dendritic cells and T cells determines whether prostaglandin E2 has a stimulatory or inhibitory effect
JP2014515258A5 (enExample)
JP2014516538A5 (enExample)
MX2013013243A (es) Medios y metodos para activar la inmunoterapia celular del cancer utilizando celulas cancerosas destruidas mediante presion hidrostatica y celulas dendriticas.
Bagirova et al. Overview of dendritic cell‐based vaccine development for leishmaniasis
Li et al. Akt promotes irradiation-induced regulatory T-cell survival in hepatocellular carcinoma
Henry et al. The roles of IL-12 and IL-23 in CD8+ T cell-mediated immunity against Listeria monocytogenes: insights from a DC vaccination model